药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Gremubamab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Gremubamab.
Tiludronic acid
Pateclizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pateclizumab.
Tiludronic acid
Dalantercept
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dalantercept.
Tiludronic acid
Margetuximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Margetuximab.
Tiludronic acid
Opicinumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Opicinumab.
Tiludronic acid
Pamrevlumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pamrevlumab.
Tiludronic acid
Bermekimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bermekimab.
Tiludronic acid
Rozanolixizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Rozanolixizumab.
Tiludronic acid
Refanezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Refanezumab.
Tiludronic acid
Bevacizumab zirconium Zr-89
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bevacizumab zirconium Zr-89.
Tiludronic acid
Emactuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emactuzumab.
Tiludronic acid
Parsatuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Parsatuzumab.
Tiludronic acid
Vobarilizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vobarilizumab.
Tiludronic acid
Lintuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lintuzumab.
Tiludronic acid
Xentuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Xentuzumab.
Tiludronic acid
Brolucizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Brolucizumab.
Tiludronic acid
Codrituzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Codrituzumab.
Tiludronic acid
Icrucumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Icrucumab.
Tiludronic acid
Isatuximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Isatuximab.
Tiludronic acid
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Anetumab ravtansine.